Publications by authors named "Seta Shahin"

Claim this Profile
C
Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19.
Mary Nilsson, Brenda Crowe, Greg Anglin, Greg Ball, Melvin Munsaka, Seta Shahin

Stat Biopharm Res· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib.
Gary A Ulaner, Cristina Saura, Sarina A Piha-Paul, Ingrid Mayer, David Quinn, Seta Shahin

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choosing Appropriate Metrics to Evaluate Adverse Events in Safety Evaluation.
Ying Zhou, Chunlei Ke, Qi Jiang, Seta Shahin, Steven Snapinn

Ther Innov Regul Sci· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.
Howard A Burris, Chandra P Belani, Peter A Kaufman, Alan N Gordon, Lee S Schwartzberg, Seta Shahin

J Oncol Pract· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
J Randolph Hecht, Edith Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, Seta Shahin

J Clin Oncol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
Lodovico Balducci, Hafez Al-Halawani, Veena Charu, Jennifer Tam, Seta Shahin

Oncologist· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A combined analysis of average relative dose intensity in the chemotherapy of solid tumors with pegfilgrastim or filgrastim support.
Jeffrey Crawford, Michael Green, Brian McGuire, Seta Shahin

Support Cancer Ther· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin.
James K Stoller, Farshid Rouhani, Mark Brantly, Seta Shahin, Raed A Dweik

Chest· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis